Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Allogeneic Epstein-Barr Virus-Specific Cytotoxic T-Lymphocytes, covering 2013-12-18 to 2013-12-18. Get the full timeline:
Most recent: Clinical Trial Update: Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma [Phase 1]